Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 5.07, 9.01 · 8-K

Precigen, Inc.

PGENNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 18, 2026 (the “2026 Annual Meeting”), the Company’s stockholders approved an amendment to the Precigen, Inc.…

Filed Jun 24, 2026Accepted Jun 24, 2026, 4:07 PM EDTCIK 1356090Accession 0000950103-26-009441
Share

Company context

Current securities

Recent company filings

  1. Results of Operations and Financial ConditionNov 5, 2026
  2. 10-Q filingNov 4, 2026
  3. 4 filingAug 28, 2026
  4. 4 filingAug 25, 2026
  5. SCHEDULE 13G/A - filed by Merck KGaA regarding PRECIGEN, INC.Aug 7, 2026

Registered securities in this filing

Precigen, Inc. · 8-K · Filed 2026-06-24

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, No Par Value

Symbol
PGEN
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-06-18

Dimensions: Not supplied

Accession 000095010326009441 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 5.07, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 18, 2026 (the “2026 Annual Meeting”), the Company’s stockholders approved an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended (the “2023 Plan”), to increase the number of shares of common stock available for issuance thereunder by 7 million (the “2023 Plan Amendment No. 3”). The approval of the 2023 Plan Amendment No. 3 had been previously approved by the Company’s Board of Directors (the “Board”), subject to stockholder approval. The 2023 Plan Amendment No. 3 amends the 2023 Plan, which was previously approved by the Company’s stockholders on June 8, 2023, and subsequently amended by the Company’s stockholders on July 5, 2024 and June 26, 2025. The principal features of the 2023 Plan Amendment No. 3 are described in detail under “Proposal 4 - Approval of an Amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as Amended (the “2023 Plan”)” of the Company’s Definitive Proxy Statement on Schedule 14A for the 2026 Annual Meeting filed by the Company with the Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”). The full text of the 2023 Plan Amendment No. 3 is attached as Annex A to the Proxy Statement.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Security Holders. At the 2026 Annual Meeting, the Company’s stockholders (i) elected each of the persons listed below as a director for a one-year term, (ii) ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, (iii) approved a non-binding advisory resolution approving the compensation of the named executive officers, and (iv) approved the 2023 Plan Amendment No. 3. Proposal 1 - Election of directors. For Against Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────────────────────────────────── Randal Kirk 207,060,147 5,072,069 154,634 61,452,809 Nancy Howell Agee 206,723,562 4,245,863 1,317,425 61,452,809 Cesar Alvarez 198,441,890 12,508,463 1,336,497 61,452,809 Steven Frank 205,741,016 5,182,858 1,362,976 61,452,809 Vinita Gupta 153,104,242 57,856,824 1,325,784 61,452,809 Fred Hassan 206,611,453 4,378,940 1,296,457 61,452,809 Jeffrey Kindler 206,614,657 4,373,888 1,298,305 61,452,809 Helen Sabzevari 210,626,763 1,532,092 127,995 61,452,809 James Turley 206,342,088 4,646,207 1,298,555 61,452,809 Proposal 2 - Ratification of the Appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain ───────────────────────────────────────── 272,813,907 253,969 671,783 Proposal 3 - Non-binding advisory resolution approving the compensation of the named executive officers. For Against Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────────── 208,241,739 2,790,879 1,254,232 61,452,809 Proposal 4 - Approval of an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended, to increase the number of shares of common stock which may be subject to awards thereunder by 7 million. For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────────── 207,056,264 4,996,260 234,326 61,452,809

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.